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Superoxide dismutases (SODs) are oxy-radical scavenger enzymes
that catalyse the dismutation of O-2 to H2O2 and whose decrease has
been related to tumorigenesis in several experimental models and
human cancers (e.g. see Galeotti et al, 1989; Sun, 1990). 
Over-production of reactive oxygen species (ROS) has been asso-
ciated with DNA damage and tumour induction (Okada et al, 1999).
The hypothesis of a role for such a pathogenic mechanism has been
reinforced by the observation that several oxy-radical scavenger
enzymes decrease during tumour progression, and that less differen-
tiated tumours usually have lower anti-oxidant capacity. According
to this hypothesis, it has been reported that manganese-dependent
SOD (MnSOD) over-expression in several cell types (SV40 trans-
formed fibroblast,(Bravard et al, 1992a), melanoma (Bravard et al,
1999), prostate cancer cells (Li et al, 1998) could restore a ‘normal’
phenotype, and it was suggested that this type of SOD could be
considered as an anti-oncogene (Bravard et al, 1992b). 
In contrast with this view, an increase in levels of MnSOD has
been reported in the sera of 50% of patients suffering from ovarian
cancer and neuroblastomas (Ishikawa et al, 1990; Kawamura et al,
1992). We (Landriscina et al, 1996) and others have reported that
MnSOD content in human astrocytomas increases together with
grading, in a statistically significant manner. Increase of MnSOD
levels were also observed in pleural mesothelioma (Kahlos et al,
1998) and renal carcinoma (Sarto et al, 1999). A further support to
the hypothesis that oxy-radical scavenger enzymes can be bene-
ficial to brain tumour survival comes from a report showing that
also Cu/ZnSOD increases with grading in astrocytomas (although
without reaching statistical significance), and it apparently confers
resistance to drug- and radiotherapy to the tumour itself (Yoshii
et al, 1999). Reduction of sensitivity to radiation therapy has also
been implied as the mechanism that sustains the role as negative
prognostic factor of MnSOD for local recurrence of cervical carci-
nomas (Nakano et al, 1996). The possibility that an increase of
MnSOD level is a relatively late event that boosts the malignant
potency of tumours was already suggested by our data and is
further supported by the work of Lam et al (1999) showing that
over-expression of MnSOD results in increase of cell invasiveness
in hamster cheek pouch carcinoma cells, and by data reported by
Janssen et al (1999), showing that neoplastic epithelial cells and
metastasis of colon carcinomas had levels of this enzyme higher
than intermediate dysplastic adenoma cells. 
The hypothesis that MnSOD may act as an ‘oncogene’ is also
sustained by several recent data that suggest a model in which
oxy-radicals play a relevant role in the induction of apoptosis (e.g.
see Amoroso et al, 1999; Jayanthi et al, 1999). Several reports
have highlighted the role that mitochondrial and redox-related
enzymes may play in the induction of apoptosis and, conversely, in
the escape from apoptosis during tumour induction and progres-
sion. As an example, an efflux of cytochrome c from mitochondria
has been demonstrated to be a major event in apoptosis (for a
review see Green and Reed, 1998). MnSOD has been suggested to
play a relevant role in protecting hippocampal neurons against
oxidative stress-induced apoptosis (Mattson et al, 1997), and it has
been shown to protect cells from mitochondrial initiated cell death
(Kinningham et al, 1999). 
A helpful piece of information about the role that oxy-radical
scavenger enzymes play in tumours would be to relate their levels
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of the same histological type and of the same grading that differ in
the content of a given enzyme. Were this enzyme favourable for
tumour growth (such as it would be if it is involved in protection
from induction of apoptosis), one would expect to have a worse
prognosis for those tumours that show higher levels of enzyme.
The opposite would be expected in the case that the effect of the
enzyme is detrimental for tumour progression (such as if it mainly
removes agents favouring cell proliferation or tumour progres-
sion). In our previous work (Landriscina et al, 1996) we reported
that glioblastomas showed a bimodal distribution of their MnSOD
content, and could therefore be divided in two groups, character-
ized by lower or higher amounts of MnSOD, and encompassing
approximately 30% and 70% of total glioblastomas, respectively.
Therefore in this tumour model, we are in the condition to evaluate
the potential benefit of using the MnSOD content as a prognostic
factor for this subset of brain neuroepithelial tumours. In the
present paper we compare the clinical outcome of 30 patients
bearing glioblastomas whose MnSOD content had been estab-
lished at the time of the first diagnosis. According to the criteria
reported in (Landriscina et al, 1996) patients were divided in two
groups, low MnSOD (for MnSOD content in class I and II, L.S.),
and high MnSOD (for an MnSOD content in class III or IV, H.S.),
and the survival curves were matched. As a further practical
outcome, the results of this experiment may be applied to the eval-
uation of low grade astrocytomas, among which approximately
10% show an accelerated course. 
A further point that needs to be clarified is which biological
events result in MnSOD up-regulation in brain tumours. MnSOD is
an inducible enzyme, whose up-regulation in response to ROS or
LPS (possibly via TNF) is controlled by AP-1 (which is, in turn,
under the regulation of MAP kinases signalling pathway) (Borrello
and Demple, 1997). Recent reports have also highlighted the role of
NF-kappa B in its positive regulation (Mattson et al, 1997; Xu et al,
1999). However, we have also observed that inactivation of p53
function results in over-expression of MnSOD (Pani et al, 2000),
and it has been reported that expression of wild-type p53 could
inhibit the induction of MnSOD by TNF (Shatrov et al, 2000).
Furthermore, a statistical association between high MnSOD levels
and nuclear accumulation of p53 was observed in cervical cancer
(Nakano et al, 1996). p53 plays a major role at the joint between
redox balance and apoptosis and it has been reported that p53 is
involved in up- or down-regulation of the expression of several
genes involved in the redox balance (Polyak et al, 1997). p53 inacti-
vation is a most frequent event in tumour progression, and it can
result from several molecular mechanisms, such as binding to viral
proteins, dominant inactivating mutation or deletion. Therefore,
although p53 alteration had already been studied in brain tumours of
neuroepithelial origin (see e.g. von Deimling et al, 1992; Rasheed et
al, 1994) we decided to use this model to examine the relationship
between p53 histological behaviour and high or low MnSOD level. 
MATERIALS AND METHODS 
Patients and statistical analysis 
30 consecutive patients suffering from grade IV astrocytoma were
admitted to our Neurosurgery division between June 1994 and
June 1997. The clinical characteristics of these patients are listed
in Table 1. All subjects underwent surgical ablation of the tumour
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Table 1 Clinical characteristics of glioblastoma patients 
Patient Survival (months) MnSOD9 Age (Years) Sex Residual disease KPS 
1 24 LS 67 M <10% 90 
2 3 HS 46 M >10% 60 
3 17 HS 59 F >10% 80 
4 6 HS 74 F >10% 70 
5 2 HS 63 F >10% 60 
6 12 LS 53 M >10% 80 
7 12 LS 55 M >10% 80 
8 8 HS 45 F >10% 60 
9 12 HS 31 M <10% 80 
10 8 LS 57 F >10% 70 
11 8 LS 45 M >10% 60 
12 2 HS 49 F >10% 70 
13 12 LS 57 F <10% 60 
14 3 HS 59 M >10% 60 
15 1 HS 75 F >10% 60 
16 11 LS 62 F <10% 80 
17 7 HS 40 M >10% 60 
18 4 HS 50 M >10% 70 
19 2 HS 68 F >10% 60 
20 5 HS 60 M >10% 70 
21 13 LS 45 M <10% 80 
22 5 HS 65 M >10% 60 
23 8 LS 73 F >10% 60 
24 13 HS 53 F <10% 80 
25 8 LS 60 M >10% 70 
26 6 LS 45 F >10% 60 
27 1 HS 74 F >10% 50 
28 23 LS 54 M >10% 70 
29 6 HS 65 M >10% 70 
30 14 LS 66 F >10% 70 
a LS and HS are described under Material and Methods. MnSOD is a prognostic factor for glioblastoma 531
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and intraoperative specimens were frozen soon after removal as
described below, for determination of MnSOD levels. The patients
were followed for up to two years for survival, and all of patients
died within this time lag. 15 out of 30 patients belong to the group
that was studied in our previous work (Landriscina et al, 1996). 
For statistical analysis, patients were grouped according to age,
sex, post-surgery residual disease, Karnofsky Performance Status,
MnSOD levels, as described in detail in the Results section.
Survival estimates were generated by the Kaplan-Meyer product-
limit method (Kaplan and Meyer, 1958). Survival times were
measured from the date of surgery to the date of death. The log-
rank test was used to compare the distribution of survival times in
univariate analysis and to select statistically significant factors.
The multivariate analysis was performed using the Cox propor-
tional hazard model (stepwise selection: enter limit at P < 0.1,
remove limit P > 0.15) (Cox, 1972). Relative risks were expressed
as the ratio of relative death rate in two groups (Oi/Ei, O:
observed, E: expected). A P value < 0.05 was considered as statist-
ically significant. 
Evaluation of MnSOD levels 
MnSOD content in tumour brains was evaluated using either or
both immunohistology and Western blot, as described in
Landriscina et al (1996), using a commercial anti-human MnSOD
antiserum, purchased from Calbiochem (La Jolla, Ca, USA).
Briefly, intraoperative specimens were obtained during surgical
removal of the tumours and immediately frozen. 10 mm slices were
cut and fixed in acetone-methanol (50% v/v), washed three times
in phosphate buffered saline 0.1 M (PBS) and treated with protein
blocking agent (Immunon-Lipshaw, Pittsburg, PA, USA). Slices
were incubated with anti-human MnSOD antiserum or appropriate
control serum diluted according to manufacturer’s instruction and
later with alkaline phosphatase conjugated antibody, followed by
BCIP/NBT. Sequential slices were evaluated in order to confirm
the histological grading of the specimen. For Western blot,
homogenates of samples were immuno-precipitated and loaded on
a 12.5% gel for SDS-PAGE. Gels were blotted onto nitrocellulose
paper and stained for MnSOD as described (Ria et al, 1993). 
The results were expressed on a semiquantitative scale in
comparison with human liver (++++ in both immunohistology and
Western blot) and normal glia (+ in Western blot and – in immuno-
histology). Intermediate values in immunohistology were given
either for lower intensity of staining throughout the entire slice, or
for intense staining of isolated cells or of small areas. Necrotic
areas (when present) were excluded in weighing the level of
MnSOD or p53. For both Western blot and immunostaining the
results were scored by three independent observers and in a blind
fashion with respect to histological grading. MnSOD content was
divided into Low SOD (LS) for MnSOD content ranging from – to
++, and high SOD (HS) for MnSOD content evaluated as +++ to
++++. Detailed examples for both Western blot and immuno-
histology are shown in our previous work (Landriscina et al, 1996).
Immunohistology for p53 
Between February 1996 and June 1997, 4 samples from grade
II astrocytomas, 4 from grade III astrocytomas and 9 from glio-
blastomas were also collected for immunostaining for p53 and
MnSOD. Tumour slices adjacent to those prepared for MnSOD
were fixed following the same protocol described above and
matched with mouse anti-human p53 antibody DO1 or isotype
matched antibody (Santa Cruz, San Diego CA, USA) diluted
1:1000 in PBS. This antibody recognizes both native and mutated
p53. Slides were washed 30 min later and matched with anti-
mouse alkaline phosphatases conjugated antibody, and finally
stained as described above. The evaluation of p53 status was
performed as described above for MnSOD, and giving a negative
value (N) for either no staining or the staining of few, sparse cells,
and positive (P) for presence of immunohisochemical staining on
the slice. 
RESULTS 
MnSOD content is an independent prognostic factor 
30 patients affected by glioblastoma were stratified according to
age (≤ 55, 13 patients; ³ 56, 17 patients), sex (15 male and 15
female), post-surgery residual disease (≤ 10%, 6 patients; ³ 10%,
24 patients), Karnofski Performance status (80–90, 8 patients;
60–70, 22 patients) and MnSOD levels as established by immuno-
histology and/or Western blot (Low levels (group I and II of
Landriscina et al (1996)), 13 patients; High levels (group III and IV
of Landriscina et al (1996)) 17 patients). The clinical characteristics
of each patient are listed in Table 1. The ratio between LS and HS
was 43% and 57%, thus slightly correcting our previous work
reporting a 30/70 ratio on a smaller sample. The whole group of
patients show a median survival time of 8.0 months, with
Brookmeyer-Crowley 95% confidence for median survival time
between 5.0 and 12.0 months. These data are in agreement with the
expected survival, according to current literature (Bigner et al,
1998a). Univariate analysis of the survival of the patients was
performed, and the distribution of survival times are shown in
Figure 1. Confirming literature data, KPS and post-surgery residual
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Figure 1 MnSOD, KPS and postsurgical residual disease are prognostic
factors for glioblastoma. Cumulative survival and univariate analysis of
distribution of survival times of glioblastomas are shown according to
postsurgical residual disease, KPS and MnSOD content. Patients were
grouped as described in the text in the materials and methods section. The
inclusion criteria for each group and the Mantel-Cox P values for each
prognostic factor are reported in the figure532 F Ria et al
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disease were significantly associated with the clinical outcome.
Thus, patients having 80–90 KPS showed a median of survival
time of 12.0 months (Brookmeyer-Crowley 95% confidence
interval 12.0–13.0, with mean survival time of 14.2 months) as
compared to those patients that had 60–70 KPS, whose median
survival time was 6.0 months (Brookmeyer-Crowley 95% confi-
dence interval 3.0–7.0, with mean survival time of 6.4 months).
The difference between the two groups was statistically significant
(Mantel-Cox P = 0.0043). On the other hand, patients in which
surgery was able to remove > 90% of tumour mass had a median
survival of 12.0 months (the Brookmeyer-Crowley 95% confidence
interval could not be determined; mean survival 14.2 months),
while the group whose surgery was not complete displayed a
median for survival time of 6.0 months (Brookmeyer-Crowley 95%
confidence interval 4.0–7.0; mean survival of 7.1 months). As said
above, the difference among these two groups is statistically signif-
icant (Mantel-Cox P = 0.0275). These observations confirm litera-
ture data (Devaux et al, 1993; Iacoangeli et al, 1993; Kowalczuk
et al, 1997), and ensure that the tumour population we are dealing
with is representative of the general population of patients suffering
from brain tumour that are in the conditions of undergoing surgery. 
When the survival of these patients is stratified according to
MnSOD level in the tumour, a strong link of these levels and prog-
nosis can be observed. HS patients show a median survival time of
5.0 months (95% confidence 3.0–6.0 months; mean survival 6.3
months), while LS patients have a median survival time of 12.0
months (95% confidence 8.0–12.0 months; mean survival 13.0
months). These differences were significant, with Mantel-Cox P
value = 0.0119. 
As a next step, a multivariate analysis was performed between
MnSOD, KPS and Postsurgical Residual Disease (see Table 3).
Using this statistical analysis, the presence or absence of residual
disease >10% is no longer significant (Cox multivariate model 
P = 0.5681). This effect may be due to lack of balance between the
two groups. On the other hand, both MnSOD levels and KPS
behave as independent prognostic factors (MnSOD rr = 5.11, P =
0.006; KPS rr = 6.72, P < 0.001). While these data confirm
previous observations for KPS, the independent prognostic value
of MnSOD content is an entirely new point. Thus, the difference in
MnSOD content is able to describe two distinct groups of glioblas-
tomas: a group that has low levels of MnSOD and that has a rela-
tively better prognosis, and a group that has a high level of
MnSOD and is characterized by a more severe prognosis. 
Table 2 Correlation between MnSOD level and p53 
Patient Tumour MnSOD (LS or HS)a p53b
1 Grade II astocytoma LS N 
2 Grade II astocytoma LS N 
3 Grade II astocytoma LS N 
4 Grade II astocytoma LS N 
5 Grade III astrocytoma HS P 
6 Grade III astrocytoma LS N 
7 Grade III astrocytoma LS N 
8 Grade III astrocytoma LS N 
9 Glioblastoma LS N 
10 Glioblastoma HS P 
11 Glioblastoma LS N 
12 Glioblastoma HS P 
13 Glioblastoma LS N 
14 Glioblastoma LS N 
15 Glioblastoma HS P 
16 Glioblastoma HS P 
17 Glioblastoma LS N 
aLS and HS are described under Material and Methods. bN = negative;
P = positive. 
Table 3 Grouping variables examined for significance in survival analysis 
Multivariate Covariates Univariate 
P value Coefficient SE RR  P value
Age (> 55/ ≤ 55) 0.6365 
KPI (< 80/ ³ 80) 0.0043 0.000 1.9039 0.5588 6.7181 
MnSOD (HS/LS) 0.0119 0.006 1.6312 0.4910 5.1100 
Surgery (> 90 /≤ 90) 0.0275 0.5681 
Sex (M/F) 0.3881 
A
B
Figure 2 Immunostaining for MnSOD (A) and p53 )(B) in adjacent slices of
tumour sample from patient 10 of Table 2. The arrows indicate positively
stained tumour cells infiltrating brain parenchymaMnSOD is a prognostic factor for glioblastoma 533
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p53 is always in cytosolic (inactivated) form when
MnSOD is high 
To assess to some extent the upstream mechanisms that sustain the
increase in MnSOD content in brain neuroepithelial tumours, we
next studied the expression of p53 in a series of 17 astrocytomas of
various grading. An example of immunohistology of adjacent
slices for MnSOD and p53 is shown in Figure 2, where tumour
cells infiltrating the brain parenchima are positively stained for
MnSOD (2A) and cytosolic p53 (2B). The sum of results of these
experiments is reported in Table 2. As it is shown, in all tested
astrocytomas, high MnSOD content is associated with cytoplasmic
accumulation of p53. Vice versa, samples that showed low levels
of MnSOD were negative for staining with p53-specific antibody.
In our previous work we also reported that in few cases (that did
not infringe the high statistical correlation that showed a 
P < 0.001) the Western blot and the immunohistological detection
of MnSOD were not coincident. In these cases the p53 immuno-
staining was coincident with the immunostaining and not with the
Western blot for MnSOD. When the correlation between MnSOD
level (detected by immunohistology) and cytosolic accumulation
of p53 was analysed with Fisher test for small numbers a P < 0.000
can be found. However, a caveat has to be raised due to the small
absolute number of observation. As discussed below, this observa-
tion strengthens the above mentioned proposal that MnSOD can be
down-regulated by active p53. 
DISCUSSION 
The possibility to study a relatively homogeneous group of
tumours for the correlation between amount of MnSOD and prog-
nosis has given us an opportunity to start addressing the issue of
the role of (at least one) anti-oxidant enzyme and tumorigenesis.
Thus we demonstrate that the glioblastomas can be divided into
two distinct groups on the basis of their content of MnSOD, and
that this content is able to divide them into tumour having ‘better’
(low MnSOD) or ‘worse’ (high MnSOD) prognosis. This observa-
tion has both biological and clinical relevance. 
As a first point, this observation allows us to state that the pro-
tumoral action of this enzyme is possibly more relevant than its
anti-tumoral properties, in this type of tumours. However, given the
tight relationship that we observed between increase of MnSOD
and ‘inactive status’ of p53, it may be debatable whether the higher
aggressiveness of tumour is actually linked to MnSOD or rather to
p53, with MnSOD being an epiphenomenon. From this point of
view, it gains relevance in our recent report that over-expression of
MnSOD increases growth capacity of HeLa cells under serum star-
vation (Palazzotti et al, 1999). In this culture condition, an overpro-
duction of ROS can be observed in wild-type HeLa cells that are
not able to up-regulate their MnSOD content, and that stop prolifer-
ating and become bound to cell death. MnSOD over-production
alone can rescue cells from cell death and allows them to keep on
with proliferation. According to this study, we also observed that
HT29 cells, that are able to up-regulate their MnSOD content, are
much less sensitive to serum starvation. 
In order for MnSOD to confer a selective advantage to tumour
cells, it is necessary that overexpression of MnSOD as protein
occurs together with increase of its enzyme activity. We therefore
tested MnSOD activity of 5 glioblastomas in gel (following the
method published in Palazzotti et al (1999), and we observed that it
varied according to immune staining (G. Pani, unpublished observa-
tion). These data support the hypothesis that it is MnSOD that helps
cells to escape cell death, to survive and to proliferate when stress
conditions such as growth factors deprivation or secretion of apop-
togenic cytokines occur (Mattson et al, 1997; Jayanthi et al, 1999;
Shatrov et al, 2000). In an in vivo model that has offered a similar
approach, it has been observed that the ischaemia-reperfusion killed
colon cancer cells characterized by low metastatic potential by
means of the generation of nitrogen and oxygen radicals from
hepatic sinusoid endothelial cells, and that the addition of super-
oxide dismutase could overcome this effect (Jessup et al, 1999). 
Looking at this set of data it is tempting to speculate that ROS
scavenging is an advantage for tumour cells. However, the
general view of literature information rather suggests that the
stage of tumour progression (Okada et al, 1999), the absolute
amount of ROS produced (Sung et al, 1999), the redox status of
the cell and its ability to regulate the level of pro- or anti-oxidant
enzymes are all together factors that will dictate the pro-or anti-
tumoral effect of oxidative stress and, conversely of oxy-
scavenger enzymes. Thus, it is possible that some tumour types
gain advantage from the early ROS-induced DNA modification,
while others rather benefit from the possibility to escape the
induction of apoptosis. 
As it was stated earlier, AP-1 and NF-kappa B on the positive
side and p53 on the negative one have been suggested as being the
major nuclear factors involved in MnSOD regulation. Our results
strongly support this view. Tumours displaying high levels of
MnSOD have always cytoplasmic accumulation of p53. 
With the help of MnSOD we actually describe two groups of
glioblastomas that differ both as for biological mechanisms of
progression and as for clinical outcome. A bipartition of an otherwise
homogeneous group of tumours was suggested several years ago, on
the basis of histological observations that described one group of
glioblastomas as being the evolution of a lower graded astrocytoma
and a second one that arouses directly as a grade IV tumour (Scherer,
1938, 1940; Bigner et al, 1998b). Here we describe two biologically
different groups. In the first group cytoplasmic sequestration of p53
(possibly associated with increase of signalling from membrane
receptor through MAPK and AP-1 (Landriscina, unpublished obser-
vations)) leads to over-expression of MnSOD. As said above, this
enzyme may offer a selective advantage in both proliferation and
escape from apoptosis upon stress conditions, thus conferring a more
aggressive phenotype to brain tumours. In the second group, MnSOD
fails to be up-regulated and tumours show a slower progression.
Further studies will be needed to establish whether the two histologi-
cally defined subgroups of glioblastomas are actually coincident with
the two biologically different subgroups. In any case, the use of
MnSOD as a marker may help in the future the clinical management
of glioblastomas and in defining better therapeutic strategies. 
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